Programm Freitag, 17. Januar 2025 |
Zeit |
Thema |
Moderation/Speaker |
08:30 - 09:00 |
Registration & Welcome coffee
|
|
09:00 - 09:05 |
Welcome speech
|
Helge Seifert, Prof.,University Hospital Basel, Basel, Switzerland |
09:05 - 09:10 |
«Live Surgery»
|
Peter Wiklund, MD, Prof., Karolinska Institute, Stockholm, Sweden Hosseini Aliabad Seyed Abolfazl, MD, University Hospital Basel, Basel, Switzerland
Chair: Karen Fransis, MD, PhD, University Hospital Antwerp, Edegem, Belgium Ashkan Mortezavi, PD Dr., University Hospital Zurich, Zurich, Switzerland |
09:10 - 09:15 |
Introduction – NMIBC
|
Cyrill A. Rentsch, MD, PhD, Prof., University Hospital Basel, Basel, Switzerland
Chair: Ilaria Lucca, MD, CHUV, Lausanne, Switzerland Cédric Poyet, MD, City Hospital Triemli, Zurich, Switzerland |
09:15 - 10:10 |
The potential for urinary markers to replace cystoscopy
|
Lukas Bubendorf, MD, Prof, University Hospital Basel, Basel, Switzerland |
10:10 - 10:15 |
«Live Surgery»
|
|
10:15 - 10:40 |
The future of BCG-naive NMIBC therapy
|
Paolo Gontero, MD, Prof., Ospedale Molinette, Turin, Italy |
10:40 - 10:45 |
«Live Surgery»
|
|
10:45 - 11:15 |
Coffee break (industrial exhibition)
|
|
11:15 - 11:20 |
«Live Surgery»
|
|
11:20 - 11:45 |
BCG unresponsive: Upcoming perspectives for the unfit or unwilling and beyond
|
Piyush K. Agarwal, MD, Prof., Comprehensive Cancer Research Center, The University of Chicago, Chicago, USA |
11:45 - 12:30 |
Keynote lecture:
Biomarkers guiding the future treatment of localized bladder cancer
|
Peter Black, MD, Prof., Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
Chair: Helge Seifert, Prof., University Hospital Basel, Basel, Switzerland |
12:30 - 12:35 |
«Live Surgery»
|
|
12:35 - 13:30 |
Lunch (industrial exhibition)
|
|
13:30 - 13:35 |
«Live Surgery»
|
|
13:35 - 13:40 |
Introduction – MIBC Muscle invasive bladder cancer
|
Richard Cathomas, Prof., Cantonal Hospital Graubünden, Chur, Switzerland
Chair: Roland Seiler, MD, Prof., Cantonal Hospital Biel, Switzerland Massimo Valerio, MD, Prof., HUG, Geneva, Switzerland |
13:40 - 14:05 |
From neoadjuvant to perioperative and beyond: Systemic therapy as a cornerstone
|
Stefanie Fischer, MD, Cantonal Hospital St. Gallen, St. Gallen, Switzerland |
14:05 - 14:10 |
«Live Surgery»
|
|
14:10 - 14:35 |
Bladder-sparing with TMT: The present and future
|
Ananya Choudhury, MD, The Christie NHS Foundation Trust, Manchester, Great Britain |
14:35 - 14:40 |
«Live Surgery»
|
|
14:40 - 15:10 |
Coffee break (industrial exhibition)
|
|
15:10 - 15:45 |
Tailored treatment approaches for metastatic bladder cancer
|
Yohann Loriot, MD, PhD, Prof., Gustave Roussy Cancer Institute, Villejuif, France |
15:45 - 16:10 |
Panel discussion
|
Cyrill A. Rentsch, MD, PhD, Prof., University Hospital Basel, Switzerland Richard Cathomas, MD, Prof., Cantonal Hospital Graubünden, Chur, Switzerland |
16:10 - 16:15 |
Closing remarks
|
Helge Seifert, Prof., University Hospital Basel, Basel, Switzerland |
16:15 |
Networking & Apéro riche (industrial exhibition)
|
|
|
Programm Freitag, 12. Januar 2024 |
Zeit |
Thema |
Moderation/Speaker |
08:45 - 08:55 |
Welcome speech
|
Prof. Helge Seifert |
08:55 - 09:00 |
Prostate Cancer in Switzerland
|
PD Dr. Ashkan Mortezavi On behalf of the Swiss Prostate Cancer Screening Working Group |
  |
Session 1 – Early detection
|
Chairs: Prof. Per Anders Abrahamsson (Lund University) and Prof. Cyrill Rentsch (Universitätsspital Basel) |
09:00 - 09:30 |
Prime time for organised, risk-adapted prostate cancer screening - Impact of the EU recommendations
|
Prof. Hein Van Poppel, Chair of the EAU Policy Office |
09:30 - 10:00 |
Prostate cancer screening, the current status in Europe: first results from the PRAISE-U project
|
Prof. Monique Roobol, Erasmus Medical Centre Rotterdam |
10:00 - 10:30 |
Early detection in the context of ProtecT: more harm than good?
|
Prof. Freddie Hamdy, Nuffield Department of Surgical Sciences, University of Oxford |
10:30 - 11:00 |
Coffee break
|
|
11:00 - 11:30 |
Novel strategies for prostate cancer screening – the Stockholm trials
|
Ass. Prof. Tobias Nordström, PhD, Danderyd Sjukhus / Karolinska Institutet Stockholm |
11:30 - 12:00 |
Risk adapted PSA screening - first results from the PROBASE trial
|
Prof. Peter Albers, Heinrich-Heine-University Düsseldorf |
12:00 - 12:15 |
Discussion
|
|
12:15 - 13:15 |
Lunch
|
|
  |
Session 2 – Treating high risk non-metastatic prostate cancer
|
Chairs: Prof. Derya Tilki (Martini Klinik Hamburg) and Prof. Frank Stenner (Universitätsspital Basel) |
13:15 - 13:45 |
Role of PSMA PET CT for local staging of prostate cancer
|
Prof. Irene Burger, Kantonsspital Baden |
13:45 - 14:15 |
Identifying the optimal candidates for pelvic lymph node dissection during prostatectomy
|
Prof. Alberto Briganti, Università Vita-Salute San Raffaele, Milan |
14:15 - 14:45 |
Robotic prostatectomy for high risk locally-advanced prostate cancer: techniques and outcomes from the highest volume UK centre
|
Prof. Prabhakar Rajan, University College London Hospitals |
14:45 - 15:15 |
Coffee break
|
|
15:15 - 15:45 |
Surgery or radiotherapy for locally advanced prostate cancer
|
Prof. Piet Ost, Ghent University |
15:45 - 16:15 |
Treatment intensification for high-risk, locally advanced and N+ prostate cancer
|
Prof. Silke Gillessen, Oncology Institute of Southern Switzerland, EOC, Bellinzona |
16:15 - 16:30 |
Discussion
|
|
|